Below are the most recent publications written about "Antitubercular Agents" by people in Profiles.
-
Lienhardt C, Dooley KE, Nahid P, Wells C, Ryckman TS, Kendall EA, Davies G, Brigden G, Churchyard G, Cirillo DM, Di Meco E, Gopinath R, Mitnick C, Scott C, Amanullah F, Bansbach C, Boeree M, Campbell M, Conradie F, Crook A, Daley CL, Dheda K, Diacon A, Gebhard A, Hanna D, Heinrich N, Hesseling A, Holtzman D, Jachym M, Kim P, Lange C, McKenna L, Meintjes G, Ndjeka N, Nhung NV, Nyang'wa BT, Paton NI, Rao R, Rich M, Savic R, Schoeman I, Makokotlela BS, Spigelman M, Sun E, Svensson E, Tisile P, Varaine F, Vernon A, Diul MY, Kasaeva T, Zignol M, Gegia M, Mirzayev F, Schumacher SG. Target regimen profiles for tuberculosis treatment. Bull World Health Organ. 2024 Aug 01; 102(8):600-607.
-
Onyenaka C, Idowu KA, Ha NP, Graviss EA, Olaleye OA. Anti-Tuberculosis Potential of OJT008 against Active and Multi-Drug-Resistant Mycobacterium Tuberculosis: In Silico and In Vitro Inhibition of Methionine Aminopeptidase. Int J Mol Sci. 2023 Dec 05; 24(24).
-
Lee HJ, Kim HK, Kim BS, Han KD, Park CS, Rhee TM, Park JB, Lee H, Kim YJ. Safety and effectiveness of anticoagulation with non-vitamin K antagonist oral anticoagulants and warfarin in patients on tuberculosis treatment. Sci Rep. 2023 02 04; 13(1):2060.
-
Prior AM, Sun D. Solid-Phase Synthesis of Wollamide Cyclohexapeptide Analogs. Methods Mol Biol. 2020; 2103:175-187.
-
Erwin ER, Addison AP, John SF, Olaleye OA, Rosell RC. Pharmacokinetics of isoniazid: The good, the bad, and the alternatives. Tuberculosis (Edinb). 2019 05; 116S:S66-S70.
-
Fitzgerald BL, Islam MN, Graham B, Mahapatra S, Webb K, Boom WH, Malherbe ST, Joloba ML, Johnson JL, Winter J, Walzl G, Belisle JT. Elucidation of a Human Urine Metabolite as a Seryl-Leucine Glycopeptide and as a Biomarker of Effective Anti-Tuberculosis Therapy. ACS Infect Dis. 2019 03 08; 5(3):353-364.
-
Tiwari S, van Tonder AJ, Vilch?ze C, Mendes V, Thomas SE, Malek A, Chen B, Chen M, Kim J, Blundell TL, Parkhill J, Weinrick B, Berney M, Jacobs WR. Arginine-deprivation-induced oxidative damage sterilizes Mycobacterium tuberculosis. Proc Natl Acad Sci U S A. 2018 09 25; 115(39):9779-9784.
-
Lane T, Russo DP, Zorn KM, Clark AM, Korotcov A, Tkachenko V, Reynolds RC, Perryman AL, Freundlich JS, Ekins S. Comparing and Validating Machine Learning Models for Mycobacterium tuberculosis Drug Discovery. Mol Pharm. 2018 10 01; 15(10):4346-4360.
-
Abanda NN, Djieugou? JY, Khadka VS, Pefura-Yone EW, Mbacham WF, Vernet G, Penlap VM, Deng Y, Eyangoh SI, Taylor DW, Leke RGF. Absence of hybridization with the wild-type and mutant rpoB probes in the Genotype MTBDRplus assay detects 'disputed' rifampicin mutations. Clin Microbiol Infect. 2018 Jul; 24(7):781.e1-781.e3.
-
Zhang S, Xu Z, Gao C, Ren QC, Chang L, Lv ZS, Feng LS. Triazole derivatives and their anti-tubercular activity. Eur J Med Chem. 2017 Sep 29; 138:501-513.